Biomed AI- Artificial Intelligence for Drug Discovery and Research Reports
Biomed AI, Inc.’s mission is to transform the drug discovery and development process by using Human Real-World Evidence and artificial intelligence / machine learning driven computation.
The cost to develop a new drug exceeds $2.6 billion and typically takes 15-20 years from drug screening, lab testing, animal studies, Phase 1, Phase 2 and Phase 3 clinical trials, to the stringent FDA regulatory process. Recent advances in artificial intelligence (AI) and Machine Learning may help to reverse this trend and accelerate and improve pharmaceutical research and development.
Biomed AI aims to fully integrate Human Real World Evidence (HRWE) data across the entire drug development and clinical trial life cycle, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates.
The company’s Biomed AI Platform™ transforms data into valuable insights that may accelerate discoveries and enable Biomed Industries, Inc. to advance a robust pipeline of programs in neurodegenerative diseases.
One of medicinal chemistry’s machine learning challenges is selection of the representation of molecular structure to capture as many of the relevant chemical and biological features and come as close to reality as possible.
(Ref: Alex Zhavoronkov- Mol. Pharmaceutics 2018, 15, 10, 4311–4313)
We plan to deploy our AI technology to optimize Phase 2 and Phase 3 clinical trials of our drugs for neurodegenerative diseases.
